Incannex currently has 28 projects whose proof of concept has been established in either pre-clinical, phase 1 or phase 2 clinical studies. With the growth of these diverse programs, Incannex is well positioned as a leader in the development of novel cannabinoid pharmaceuticals and psychedelic therapies. With 9 active development programs, Incannex is targeting conditions for patients with unmet medical needs.
A Diversified portfolio
Our Active Trials
Pre Clinical
CanQuit Addiction Tobacco Smoking Cessation
CannQuit-O Opioid Addiction
ReneCann Vitiligo, Psoriasis, Eczema
Phase 1
IHL-216A Concussion and TBI
Phase 2A
PSI-GAD Psilocybin for anxiety
IHL-675A Inflammatory Lung Disease
IHL-675A Rheumatoid Arthritis
IHL-675A Inflammatory Bowel Disease
Phase 2B
IHL-42X Obstructive Sleep Apnoea
28 Projects, one common goal — alleviate human suffering
View our full assets directory below. Click on the asset to reveal its full details including: Addressable Market, Development Stage, Regulatory Development Stage, Next Steps and Relevant Patents.
IHL-42X Obstructive Sleep Apnoea
Addressable Market Opportunity (in US$)
$10.4B
Stage of Development
Phase 2A completed
Regulatory Stage of Development
FDA Pre-IND completed
Next Steps
IND opening study
Relevant Patents
1 x Pending Deemed novel & inventive
IHL-675A Inflammatory Lung Disease
Addressable Market Opportunity (in US$)
$50.4B (U.S.) by 2022
Stage of Development
Pre-clinical completed
Regulatory Stage of Development
FDA Pre-IND completed
Next Steps
Phase 1 CT
Relevant Patents
2x Pending Deemed novel & inventive
IHL-675A Rheumatoid Arthritis
Addressable Market Opportunity (in US$)
$57B (U.S.) by 2022
Stage of Development
Pre-clinical completed
Regulatory Stage of Development
Next Steps
Phase 1 CT
Relevant Patents
2x Pending Deemed novel & inventive
IHL-675A Inflammatory Bowel Disease
Addressable Market Opportunity (in US$)
$20B (U.S.) by 2021
Stage of Development
Pre-clinical completed
Regulatory Stage of Development
Next Steps
Phase 1 CT
Relevant Patents
2x Pending Deemed novel & inventive
IHL-216A Concussion and TBI
Addressable Market Opportunity (in US$)
$2.9B in 2019
Stage of Development
Pre-clinical completed
Regulatory Stage of Development
FDA Pre-IND scheduled (Sept. 2022)
Next Steps
IND opening study
Relevant Patents
2x Pending Deemed novel & inventive
PSI-GAD Psilocybin for anxiety
Addressable Market Opportunity (in US$)
$57B (U.S.) by 2022
Stage of Development
Pre-clinical completed
Regulatory Stage of Development
Next Steps
Phase 1 CT
Relevant Patents
2x Pending Deemed novel & inventive
MedChew™-1401 Pain and Spasticity in Multiple Sclerosis
Addressable Market Opportunity (in US$)
$62B (Global) in 2021 (a
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-IND completed in NL and Switzerland
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™ GB Post-herpatic Neuralgia
Addressable Market Opportunity (in US$)
$3.7B (U.S.) by 2027 (n)
Stage of Development
Pre-clinical
Regulatory Stage of Development
FDA Pre-IND
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™-1502 Parkinson's Disease
Addressable Market Opportunity (in US$)
$8.05B (Global) by 2027; 6.5% CAGR (I)
Stage of Development
Pre-clinical
Regulatory Stage of Development
FDA Pre-IND
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™-1503 Dementia
Addressable Market Opportunity (in US$)
$23.9B (Global) by 2028; 7.9% CAGR (m)
Stage of Development
Pre-clinical
Regulatory Stage of Development
FDA Pre-IND
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™ RL Restless Legs Syndrome
Addressable Market Opportunity (in US$)
12.1.% prevalence of U.S. pop. (j)
Stage of Development
Pre-clinical
Regulatory Stage of Development
FDA Pre-IND
Next Steps
Phase 1
Relevant Patents
Granted
MedChew™ Dronabinol Nausea and Vomiting in Chemotherapy
Addressable Market Opportunity (in US$)
$3.1B (Global) by 2024 (e)
Stage of Development
Phase 1A completed
Regulatory Stage of Development
FDA Pre-IND completed
Next Steps
Phase 1B
Relevant Patents
Granted
APIRx 1505 Flotex Gastro: Chrohn's Disease
Addressable Market Opportunity (in US$)
$12.6B (Global) by 2024 (k)
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
Drafting
CanChew Plus Gastro: IBS
Addressable Market Opportunity (in US$)
$40B (U.S.) in 2021 (d)
Stage of Development
Phase 2A Completed
Regulatory Stage of Development
Pre-IND, ethical approval
Next Steps
Phase 2B
Relevant Patents
Granted
CanChew RX Gastro: IBD
Addressable Market Opportunity (in US$)
$2.78B (U.S.) by 2028 (r)
Stage of Development
Pre-clinica
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
Granted
SuppoCan (Suppository) Gastro: IBD
Addressable Market Opportunity (in US$)
$2.78B (U.S.) by 2028 (r)
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
Granted
CheWell Addiction: Cannabis Dependence
Addressable Market Opportunity (in US$)
$64B (U.S.) in 2021 (c)
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-IND ready for submission
Next Steps
Phase 1
Relevant Patents
Drafting
CanQuit Addiction Tobacco Smoking Cessation
Addressable Market Opportunity (in US$)
$47.75B (Global) by 2024, 17.3% CAGR (o)
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
Granted
CannQuit-O Opioid Addiction
Addressable Market Opportunity (in US$)
$64B (U.S.) in 2021 (c)
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
Phase 1
Relevant Patents
Granted
APIRx-1601 Skin: Vitiligo
Addressable Market Opportunity (in US$)
$0.1B (Global) in 2021 (b)
Stage of Development
Phase 2 completed
Regulatory Stage of Development
Pre-IND drafting
Next Steps
Phase 1
Relevant Patents
2x Granted, 1x Pending
APIRx-1602 Skin: Psoriasis
Addressable Market Opportunity (in US$)
$0.5B (Global) in 2021 (b)
Stage of Development
Phase 2A completed
Regulatory Stage of Development
Pre-IND drafting
Next Steps
Phase 1
Relevant Patents
2x Granted, 1x Pending
APIRx-1603 Skin: Atopic Dermatitis
Addressable Market Opportunity (in US$)
$1.1B (Global) in 2021 (b)
Stage of Development
Phase 2A completed
Regulatory Stage of Development
Pre-IND drafting
Next Steps
Phase 1
Relevant Patents
2x Granted, 1x Pending
APIRx-1701 Opth: Glaucoma
Addressable Market Opportunity (in US$)
$10.4B (Global) by2026, 6.3% CAGR (g)
Stage of Development
Pre-clinical
Regulatory Stage of Development
Pre-regulatory
Next Steps
In vitro studies
Relevant Patents
Granted
APIRx-1702 Opth: Dry Eye Syndrome
Addressable Market Opportunity (in US$)
$6.6B (Global) by 2027, 6.4% CAGR (p)
Stage of Development
Pre-clinica
Regulatory Stage of Development
Pre-regulatory
Next Steps
In vitro studies
Relevant Patents
Granted
APIRx-1801 Ultrapure THC
Addressable Market Opportunity (in US$)
$31.5B (Global) by 2030; 18.6% CAGR (q)
Stage of Development
Developed
Regulatory Stage of Development
Next Steps
Relevant Patents
Granted
APIRx-1802 Ultrapure CBD
Addressable Market Opportunity (in US$)
$31.5B (Global) by 2030; 18.6% CAGR (q)
Stage of Development
Developed
Regulatory Stage of Development
Next Steps
Relevant Patents
Granted
APIRx-1803 Ultrapure CBG
Addressable Market Opportunity (in US$)
$31.5B (Global) by 2030; 18.6% CAGR (q)
Stage of Development
Developed
Regulatory Stage of Development
Next Steps
Relevant Patents
Granted
Key Benfits
Established drug formulations with data packages necessary for regulatory applications.
Proof of concept data from pre-clinical and clinical studies supporting the proposed therapeutic applications.
Regulatory filings for multiple drug products.
Granted and pending patents for manufacturing methods, drug formulations and methods of use to treat a range of conditions.
Covering the entire drug development process from raw materials to patient dosing.
Different cannabinoid development strategy than IHL’s current programs.
Subscribe
Stay up to date with Incannex’s research and development program.